Navigation Links
NeurogesX Presents Two Posters at 61st Annual American Academy of Neurology Annual Meeting
Date:4/29/2009

betes.

An estimated 8% of the world's population suffers from neuropathic pain. Treatments to address the estimated 6.0 million U.S. neuropathic pain sufferers generated over $3.5 billion in 2007 U.S. sales, while an estimated 3.0 million people in Europe suffer from neuropathic pain. The market for neuropathic pain is quickly growing due to the rise in the aging population, diabetes, life expectancy for HIV-positive individuals, and heightened awareness among the medical community. Peripheral neuropathic pain syndromes can be difficult to treat and current treatment options are often limited by poor tolerability, the need for titration, and administration of multiple daily doses.

About NeurogesX, Inc.

NeurogesX (NASDAQ: NGSX) is a biopharmaceutical company focused on developing and commercializing novel pain management therapies. Its initial focus is on chronic peripheral neuropathic pain, including PHN, HIV-DSP and PDN. NeurogesX' late stage product portfolio is led by its product candidate Qutenza, a dermal patch designed to manage pain associated with peripheral neuropathic pain conditions, that the Company believes offers significant advantages over other pain therapies. NeurogesX submitted a new drug application (NDA) for Qutenza to the U.S. Food and Drug Administration (FDA) in October 2008 for PHN, which was accepted for filing by the FDA in December 2008. A marketing authorization application (MAA) for Qutenza received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) recommending approval for peripheral neuropathic pain in non-diabetic adults alone or in combination with other medicinal products for pain. NeurogesX is currently awaiting the European Commission's decision on the CHMP's opinion.

NeurogesX' second most advanced product candidate, NGX-
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. NeurogesX to Hold Conference Call to Discuss Fourth Quarter and Year-End 2008 Financial Results and European Regulatory Update
2. NeurogesX Qutenza(TM) (NGX-4010) Receives Positive Committee Recommendation in European Union
3. NeurogesX to Present at 11th Annual BIO CEO & Investor Conference
4. NeurogesX to Present at Rodman & Renshaw 10th Annual Healthcare Conference
5. NeurogesX Reports Third Quarter 2008 Results
6. NeurogesX to Report Third Quarter 2008 Financial Results
7. NeurogesX Submits NDA for NGX-4010 Dermal Capsaicin Patch for Treatment of Postherpetic Neuralgia (PHN)
8. NeurogesX Responds to EMEAs Day 120 Questions
9. NeurogesX to Present at Morgan Stanley Global Healthcare Unplugged Conference
10. NeurogesX Reports Second Quarter 2008 Results
11. NeurogesX to Report Second Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... , May 17, 2013  Insero Health, Inc., a ... in epilepsy and related neurological disorders, is today reporting ... lead compound INS001 in patients with drug-resistant epilepsy.  The ... Device Trials (AED) Xll meeting by Dr. ... Chairman of Insero,s Scientific Advisory Board.  In this study, ...
(Date:5/17/2013)... RURO Inc. is pleased to announce ... refinement to the smart management solution. , ezColony, ... methodical management for transgenic animal colonies, genotyping and ... platform provides user access with a plethora of ... emphasize streamlined tasks, such as animal relocation to ...
(Date:5/17/2013)... 2013 Tooth decay is an epidemic in ... of the disease. The World Health Organization says that worldwide, ... adults have cavities. What are the long-term effects of this ... strong connection between the oral bacterial imbalance and serious systemic ... rampant, yet it is also 100% preventable? Answer: there has ...
(Date:5/16/2013)... Oven Industries, Inc. has been an industry leader ... since 1964. Expertly designed, the proportional-integral-derivative PID temperature ... As one of the most commonly used ... feedback system, which helps minimize errors. With three-term control, ... process, using a control element, like a valve or ...
Breaking Biology Technology:Insero Health Reports Positive Data on Phase I Trial of Novel Therapy for Drug-resistant Epilepsy 2RURO Introduces ezColony 4.1 – The Versatile Transgenic Animal Colony Management Software 2Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 2Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 3New PID Temperature Controllers Announced by Oven Industries Inc. 2
... Ralph Kauten. Source: Teresa Esser. Ralph is one of ... of bioscience, said Frank Langley, president and CEO of Point ... Kauten to admit that his success in high-tech entrepreneurship is ... Kauten said in an interview. Ive been a lucky guy. ...
... the first debate of Wisconsin's U.S. Senate campaign, ... embryonic stem cells as little more than an inconsequential ... stem cell research that uses adult stem cells or ... uses human embryonic stem cells. , ,Technology is going ...
... innovative thinker has a lot of hard work to do ... at the Wisconsin Innovation Service Center s Ideas to ... ,Industry leaders, CEOs, lawyers and successful inventors came to share ... looking for a way to rise above the crowd. , ...
Cached Biology Technology:Ralph Kauten on how to raise angel financing 2Ralph Kauten on how to raise angel financing 3Ralph Kauten on how to raise angel financing 4It's 99 percent certain: Research cannot rely on adult stem cells alone 2It's 99 percent certain: Research cannot rely on adult stem cells alone 3More than ideas needed to make profits, experts say 2
(Date:5/16/2013)... can trigger hematopoiesis at sites outside the bone marrow ... of Ludwig-Maximilians-Universitaet (LMU) in Munich now show that a ... formation of blood cells. , Balanced hematopoiesis is essential ... development, hematopoiesis takes place mainly in the liver and ... bone marrow, and this tissue normally serves as the ...
(Date:5/16/2013)... around the world are meeting next week in ... showcase the latest in research findings about the ... understanding the disorders that affect them., "Canada is ... will showcase the best of neuroscience research done ... President of the Canadian Association for Neuroscience. He ...
(Date:5/16/2013)... us don,t ponder our pulses outside of the gym. But ... monitor heart health. , Zhenan Bao, a professor of chemical ... a dollar bill and no wider than a postage stamp. ... the wrist, is sensitive enough to help doctors detect stiff ... be used to continuously track heart health and provide doctors ...
Breaking Biology News(10 mins):Herpes infections: Natural killer cells activate hematopoiesis 27th Annual Canadian Neuroscience Meeting, Toronto, May 20-24, 2013 2Stanford engineers monitor heart health using paper-thin flexible 'skin' 2Stanford engineers monitor heart health using paper-thin flexible 'skin' 3
... present in some living animal groups today has taken ... new evidence shows the feature is at least 100 ... Ludwig-Maximilians-Universitt Munich (Germany), has led an international team of ... collections. Their research has revealed fossilised evidence for reproduction ...
... Duke University have developed a laboratory robot that can successfully ... needle to its exact location - all without the need ... researchers to believe that in the future, such a robot ... but might also be used for such medical procedures as ...
... 18, 2009) - Omega-3 fatty acids found in fatty ... progression of age-related macular degeneration (AMD), but the benefits ... whether certain supplements are taken, report researchers at the ... USDA Human Nutrition Research Center on Aging (HNRCA) at ...
Cached Biology News:Size did matter 2Autonomous robot detects shrapnel 2Autonomous robot detects shrapnel 3Omega-3 fatty acids appear to impact AMD progression 2Omega-3 fatty acids appear to impact AMD progression 3
Rabbit polyclonal to Dishevelled 2 ( Abpromise for all tested applications). entrezGeneID: 1856 SwissProtID: O14641...
... 2 - BSA and Azide free ... applications). Antigen: ... corresponding to C terminal amino acids ... Entrez GeneID: 2064 ...
Anti human PPAR gamma2 mouse monoclonal antibody...
Anti-Potassium Channel Kv2.2 Immunogen: Synthetic peptide from rat Kv2.2. Available Date: 38376...
Biology Products: